GLOBUS MEDICAL INC - A (GMED) Fundamental Analysis & Valuation

NYSE:GMED • US3795772082

87.1 USD
-2.19 (-2.45%)
At close: Mar 6, 2026
87.1 USD
0 (0%)
After Hours: 3/6/2026, 8:22:52 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This GMED fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

Overall GMED gets a fundamental rating of 7 out of 10. We evaluated GMED against 184 industry peers in the Health Care Equipment & Supplies industry. GMED scores excellent points on both the profitability and health parts. This is a solid base for a good stock. GMED is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, GMED could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

8

1. GMED Profitability Analysis

1.1 Basic Checks

  • In the past year GMED was profitable.
  • In the past year GMED had a positive cash flow from operations.
  • In the past 5 years GMED has always been profitable.
  • In the past 5 years GMED always reported a positive cash flow from operatings.
GMED Yearly Net Income VS EBIT VS OCF VS FCFGMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • GMED's Return On Assets of 10.14% is amongst the best of the industry. GMED outperforms 91.85% of its industry peers.
  • GMED's Return On Equity of 11.76% is amongst the best of the industry. GMED outperforms 86.96% of its industry peers.
  • With an excellent Return On Invested Capital value of 9.75%, GMED belongs to the best of the industry, outperforming 88.59% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for GMED is below the industry average of 8.92%.
  • The 3 year average ROIC (5.99%) for GMED is below the current ROIC(9.75%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 10.14%
ROE 11.76%
ROIC 9.75%
ROA(3y)4.84%
ROA(5y)6.26%
ROE(3y)5.77%
ROE(5y)7.23%
ROIC(3y)5.99%
ROIC(5y)7.61%
GMED Yearly ROA, ROE, ROICGMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • GMED's Profit Margin of 18.30% is amongst the best of the industry. GMED outperforms 93.48% of its industry peers.
  • In the last couple of years the Profit Margin of GMED has grown nicely.
  • The Operating Margin of GMED (18.30%) is better than 89.67% of its industry peers.
  • GMED's Operating Margin has improved in the last couple of years.
  • GMED has a Gross Margin of 67.41%. This is in the better half of the industry: GMED outperforms 72.83% of its industry peers.
  • In the last couple of years the Gross Margin of GMED has remained more or less at the same level.
Industry RankSector Rank
OM 18.3%
PM (TTM) 18.3%
GM 67.41%
OM growth 3Y-7.48%
OM growth 5Y4.58%
PM growth 3Y-0.53%
PM growth 5Y7.14%
GM growth 3Y-3.16%
GM growth 5Y-1.43%
GMED Yearly Profit, Operating, Gross MarginsGMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. GMED Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GMED is destroying value.
  • The number of shares outstanding for GMED has been reduced compared to 1 year ago.
  • Compared to 5 years ago, GMED has more shares outstanding
  • GMED has a better debt/assets ratio than last year.
GMED Yearly Shares OutstandingGMED Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
GMED Yearly Total Debt VS Total AssetsGMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • An Altman-Z score of 11.56 indicates that GMED is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 11.56, GMED belongs to the top of the industry, outperforming 92.39% of the companies in the same industry.
  • The Debt to FCF ratio of GMED is 0.00, which is an excellent value as it means it would take GMED, only 0.00 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.00, GMED belongs to the best of the industry, outperforming 93.48% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that GMED is not too dependend on debt financing.
  • The Debt to Equity ratio of GMED (0.00) is better than 75.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.56
ROIC/WACC0.96
WACC10.12%
GMED Yearly LT Debt VS Equity VS FCFGMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.3 Liquidity

  • GMED has a Current Ratio of 4.26. This indicates that GMED is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 4.26, GMED is in the better half of the industry, outperforming 69.02% of the companies in the same industry.
  • A Quick Ratio of 2.74 indicates that GMED has no problem at all paying its short term obligations.
  • GMED has a Quick ratio of 2.74. This is in the better half of the industry: GMED outperforms 61.96% of its industry peers.
Industry RankSector Rank
Current Ratio 4.26
Quick Ratio 2.74
GMED Yearly Current Assets VS Current LiabilitesGMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. GMED Growth Analysis

3.1 Past

  • GMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.39%, which is quite impressive.
  • GMED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.84% yearly.
  • Looking at the last year, GMED shows a quite strong growth in Revenue. The Revenue has grown by 16.65% in the last year.
  • Measured over the past years, GMED shows a very strong growth in Revenue. The Revenue has been growing by 30.08% on average per year.
EPS 1Y (TTM)27.39%
EPS 3Y24.56%
EPS 5Y22.84%
EPS Q2Q%52.38%
Revenue 1Y (TTM)16.65%
Revenue growth 3Y42.17%
Revenue growth 5Y30.08%
Sales Q2Q%25.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.57% on average over the next years. This is quite good.
  • GMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.38% yearly.
EPS Next Y12.98%
EPS Next 2Y11.84%
EPS Next 3Y11.36%
EPS Next 5Y11.57%
Revenue Next Year9.49%
Revenue Next 2Y7.96%
Revenue Next 3Y7.68%
Revenue Next 5Y7.38%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GMED Yearly Revenue VS EstimatesGMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
GMED Yearly EPS VS EstimatesGMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

6

4. GMED Valuation Analysis

4.1 Price/Earnings Ratio

  • GMED is valuated rather expensively with a Price/Earnings ratio of 21.77.
  • GMED's Price/Earnings ratio is a bit cheaper when compared to the industry. GMED is cheaper than 79.89% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of GMED to the average of the S&P500 Index (26.29), we can say GMED is valued inline with the index average.
  • A Price/Forward Earnings ratio of 19.27 indicates a rather expensive valuation of GMED.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of GMED indicates a rather cheap valuation: GMED is cheaper than 80.98% of the companies listed in the same industry.
  • GMED's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.57.
Industry RankSector Rank
PE 21.78
Fwd PE 19.27
GMED Price Earnings VS Forward Price EarningsGMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GMED is valued cheaply inside the industry as 82.07% of the companies are valued more expensively.
  • GMED's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GMED is cheaper than 88.59% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.35
EV/EBITDA 14.1
GMED Per share dataGMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • GMED's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of GMED may justify a higher PE ratio.
PEG (NY)1.68
PEG (5Y)0.95
EPS Next 2Y11.84%
EPS Next 3Y11.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GMED Dividend Analysis

5.1 Amount

  • GMED does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GMED Fundamentals: All Metrics, Ratios and Statistics

GLOBUS MEDICAL INC - A

NYSE:GMED (3/6/2026, 8:22:52 PM)

After market: 87.1 0 (0%)

87.1

-2.19 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-01
Inst Owners101.55%
Inst Owner Change-0.36%
Ins Owners0.69%
Ins Owner Change1.12%
Market Cap11.78B
Revenue(TTM)2.94B
Net Income(TTM)537.87M
Analysts78.18
Price Target107.03 (22.88%)
Short Float %4.21%
Short Ratio3.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.49%
Min EPS beat(2)9.18%
Max EPS beat(2)47.79%
EPS beat(4)3
Avg EPS beat(4)14.55%
Min EPS beat(4)-10.39%
Max EPS beat(4)47.79%
EPS beat(8)7
Avg EPS beat(8)15.89%
EPS beat(12)9
Avg EPS beat(12)10.63%
EPS beat(16)11
Avg EPS beat(16)7.24%
Revenue beat(2)2
Avg Revenue beat(2)2.03%
Min Revenue beat(2)1.39%
Max Revenue beat(2)2.67%
Revenue beat(4)2
Avg Revenue beat(4)-0.94%
Min Revenue beat(4)-6.31%
Max Revenue beat(4)2.67%
Revenue beat(8)6
Avg Revenue beat(8)-0.05%
Revenue beat(12)8
Avg Revenue beat(12)-0.37%
Revenue beat(16)8
Avg Revenue beat(16)-0.79%
PT rev (1m)0.97%
PT rev (3m)18.02%
EPS NQ rev (1m)1.2%
EPS NQ rev (3m)3.63%
EPS NY rev (1m)1.12%
EPS NY rev (3m)16.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.18%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)2.67%
Valuation
Industry RankSector Rank
PE 21.78
Fwd PE 19.27
P/S 4.01
P/FCF 20.35
P/OCF 15.64
P/B 2.58
P/tB 4.92
EV/EBITDA 14.1
EPS(TTM)4
EY4.59%
EPS(NY)4.52
Fwd EY5.19%
FCF(TTM)4.28
FCFY4.92%
OCF(TTM)5.57
OCFY6.4%
SpS21.73
BVpS33.81
TBVpS17.69
PEG (NY)1.68
PEG (5Y)0.95
Graham Number55.17
Profitability
Industry RankSector Rank
ROA 10.14%
ROE 11.76%
ROCE 11.19%
ROIC 9.75%
ROICexc 11.03%
ROICexgc 22.66%
OM 18.3%
PM (TTM) 18.3%
GM 67.41%
FCFM 19.7%
ROA(3y)4.84%
ROA(5y)6.26%
ROE(3y)5.77%
ROE(5y)7.23%
ROIC(3y)5.99%
ROIC(5y)7.61%
ROICexc(3y)6.95%
ROICexc(5y)9.44%
ROICexgc(3y)15.9%
ROICexgc(5y)15.96%
ROCE(3y)6.88%
ROCE(5y)8.74%
ROICexgc growth 3Y10.02%
ROICexgc growth 5Y14.9%
ROICexc growth 3Y-7.63%
ROICexc growth 5Y4.43%
OM growth 3Y-7.48%
OM growth 5Y4.58%
PM growth 3Y-0.53%
PM growth 5Y7.14%
GM growth 3Y-3.16%
GM growth 5Y-1.43%
F-Score8
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 63.01%
Cap/Sales 5.93%
Interest Coverage 250
Cash Conversion 92.5%
Profit Quality 107.65%
Current Ratio 4.26
Quick Ratio 2.74
Altman-Z 11.56
F-Score8
WACC10.12%
ROIC/WACC0.96
Cap/Depr(3y)54.18%
Cap/Depr(5y)70.45%
Cap/Sales(3y)5.17%
Cap/Sales(5y)5.74%
Profit Quality(3y)211.86%
Profit Quality(5y)167.52%
High Growth Momentum
Growth
EPS 1Y (TTM)27.39%
EPS 3Y24.56%
EPS 5Y22.84%
EPS Q2Q%52.38%
EPS Next Y12.98%
EPS Next 2Y11.84%
EPS Next 3Y11.36%
EPS Next 5Y11.57%
Revenue 1Y (TTM)16.65%
Revenue growth 3Y42.17%
Revenue growth 5Y30.08%
Sales Q2Q%25.73%
Revenue Next Year9.49%
Revenue Next 2Y7.96%
Revenue Next 3Y7.68%
Revenue Next 5Y7.38%
EBIT growth 1Y63.49%
EBIT growth 3Y31.53%
EBIT growth 5Y36.04%
EBIT Next Year54.14%
EBIT Next 3Y22.05%
EBIT Next 5Y18.95%
FCF growth 1Y42.89%
FCF growth 3Y76.95%
FCF growth 5Y33.79%
OCF growth 1Y44.72%
OCF growth 3Y61.61%
OCF growth 5Y30.54%

GLOBUS MEDICAL INC - A / GMED FAQ

What is the ChartMill fundamental rating of GLOBUS MEDICAL INC - A (GMED) stock?

ChartMill assigns a fundamental rating of 7 / 10 to GMED.


Can you provide the valuation status for GLOBUS MEDICAL INC - A?

ChartMill assigns a valuation rating of 6 / 10 to GLOBUS MEDICAL INC - A (GMED). This can be considered as Fairly Valued.


Can you provide the profitability details for GLOBUS MEDICAL INC - A?

GLOBUS MEDICAL INC - A (GMED) has a profitability rating of 8 / 10.


What are the PE and PB ratios of GLOBUS MEDICAL INC - A (GMED) stock?

The Price/Earnings (PE) ratio for GLOBUS MEDICAL INC - A (GMED) is 21.78 and the Price/Book (PB) ratio is 2.58.


Can you provide the expected EPS growth for GMED stock?

The Earnings per Share (EPS) of GLOBUS MEDICAL INC - A (GMED) is expected to grow by 12.98% in the next year.